Cancer Center Support Grant

研究计划-新泽西州罗格斯癌症研究所 项目摘要/摘要 新泽西州罗格斯癌症研究所(CINJ)是一个矩阵/财团(与普林斯顿大学)和新 泽西州唯一一家由NCI指定的综合癌症中心，为890万不同人群提供服务。 CINJ将新泽西州主要研究机构的优势和资源集中在解决癌症上 在其集水区(新泽西州)的负担。CINJ的快速增长证实了最初的愿景，即 全国最大的公立健康科学大学将迅速产生NCI指定的癌症 中心。CINJ有227名成员(206名罗格斯大学成员，19名普林斯顿大学成员，2名合作成员)。国家癌症登记处 和监测、流行病学和最终结果(SEER)计划于2011年转移到CINJ，因此 2013年，CINJ成为罗格斯大学的独立学院，优化了CINJ的 增长潜力、跨学科协作以及对整个集水区的影响。2018财年，CINJ 从罗格斯大学和普林斯顿大学、州政府、卫生系统和慈善机构获得了超过6800万美元的支持。 直接同行评审支持增加了约16%。会员出版了3664份以癌症为主题的出版物 2011年(20%为方案间，24%为方案内，55%为机构间)。2017年1月，史蒂文·K·利布蒂 被任命为CINJ主任兼罗格斯大学生物医学和健康癌症项目副校长 科学(RBHS)。在与RWJ Barnabas卫生系统的战略合作伙伴关系中，Libuti被任命为高级 肿瘤学服务副总裁。CINJ现在的定位是协调癌症研究和护理 在它的集水区。迭代的战略规划过程导致研究的重组 增加合作、癌症焦点、翻译和研究人员发起的临床试验的计划。这五个人 项目包括：1)癌症代谢与生长(CMG)，2)基因组不稳定性与癌症遗传学(GICG)， 3)癌症药理学(CP)，4)临床研究和精确治疗(CIPT)，5)癌症 预防控制(CPC)。这些项目由八个共享资源(Biomedical 信息学、生物识别、生物信息库和组织病理学服务、综合基因组学、FLOW 细胞学/细胞分类、基因组编辑、代谢组学和研究药学)，两个开发中的共享 资源(免疫监测、小分子筛查)。CINJ在全州的权威来自于它的 作为NCI指定的唯一癌症中心；新泽西州广泛和直接支持 作为国家肿瘤学资源；有机会在 全国最多样化和人口最稠密的州；以及跨 优秀的研究机构。这支持了CINJ减轻其集水区癌症负担的使命 通过推进癌症研究、预防、筛查和教育。

RESEARCH PLAN – RUTGERS CANCER INSTITUTE OF NEW JERSEY OVERALL PROJECT SUMMARY/ABSTRACT The Rutgers Cancer Institute of New Jersey (CINJ) is a matrix/consortium (with Princeton University) and New Jersey’s only NCI-designated Comprehensive Cancer Center, serving a diverse population of 8.9 million people. CINJ focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). The rapid trajectory of CINJ’s growth validated the initial vision that one of the Nation’s largest public universities of the health sciences would rapidly bring forth an NCI-designated Cancer Center. CINJ has 227 members (206 Rutgers, 19 Princeton, and 2 collaborating). The State Cancer Registry and Surveillance, Epidemiology, and End Results (SEER) Program was moved to CINJ in 2011, and as a result of state legislation in 2013, CINJ became an independent institute of Rutgers University, optimizing CINJ’s potential for growth, transdisciplinary collaboration, and impact across the catchment area. In FY2018, CINJ received over $68 million in support from Rutgers and Princeton, the State, the Health System, and philanthropy. Direct peer-reviewed support increased ~16%. Members published 3,664 cancer focused publications since 2011 (20% inter- and 24% intra-programmatic, 55% inter-institutional). In January 2017, Steven K. Libutti was appointed Director of CINJ and Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences (RBHS). In a strategic partnership with the RWJBarnabas Health System, Libutti was named Senior Vice President for Oncology Services. CINJ is now positioned to coordinate both cancer research and care throughout its catchment area. An iterative strategic planning process resulted in reorganization of research Programs to increase collaborations, cancer focus, translation, and investigator-initiated clinical trials. These five Programs are: 1) Cancer Metabolism and Growth (CMG), 2) Genomic Instability and Cancer Genetics (GICG), 3) Cancer Pharmacology (CP), 4) Clinical Investigations and Precision Therapeutics (CIPT), and 5) Cancer Prevention and Control (CPC). These Programs are supported by eight shared resources (Biomedical Informatics, Biometrics, Biorepository and Histopathology Services, Comprehensive Genomics, Flow Cytometry/Cell Sorting, Genome Editing, Metabolomics, and Research Pharmacy), with two developing shared resources (Immune Monitoring, Small Molecule Screening). The Statewide authority of CINJ derives from its status as the only NCI-designated Cancer Center; extensive and direct support by the State of New Jersey to serve as the State’s oncology resource; opportunities to conduct translational and population research within the most diverse and densely populated State in the nation; and the synergistic opportunities for collaboration across outstanding research institutions. This supports CINJ’s mission to reduce the burden of cancer in its catchment by advancing cancer research, prevention, screening and education.